CTOs on the Move

Tallac Therapeutics

www.tallactherapeutics.com

 
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Tallac Therapeutics raised $62M on 12/01/2020

Similar Companies

Selvita

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita is also a major shareholder in Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine. In January 2021, Selvita acquired 100% of shares in Fidelta d.o.o., substantially expanding its scope of drug discovery services in infectious diseases, inflammation, and fibrosis and building a competitive advantage in areas such as DMPK, in vivo pharmacology, and toxicology. Selvita was established in 2007 and currently employs almost 800 professionals, of which over 40% hold a Ph.D. title. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland, while Fidelta is located in Zagreb, Croatia. Selvita`s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.

Thermo Fisher Scientific

Thermo Fisher Scientific is an American supplier of scientific instrumentation, reagents and consumables, and software services.

Orsini Healthcare

Orsini Healthcare is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Heart

Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XyloCor

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.